Health
Promising Data for Preop Checkpoint Inhibition in NSCLC – MedPage Today
Major response rate of 21%, encouraging survival with single-agent atezolizumab
A fifth of patients with operable early-stage non-small cell lung cancer (NSCLC) had major pathologic responses (MPR) and more than 40% had pathologic downstaging after neoadjuvant atezolizumab (Tecentriq), a prospective multicenter trial showed.
Results showed that 30 of 144 evaluable patients attained MPR, including pathologic complete response (pCR) in 10 patients. Downstaging occurred in 66 of 155 evaluable patients following preoperative treatment with atezolizumab, and 29 patients had upstaging…
-
General22 hours agoDonald Trump’s initial 10 per cent tariff takes effect
-
General21 hours agoJaguar Land Rover in UK pauses shipments to US
-
General18 hours agoTexas opens probe into Kellogg’s health claims, dyes
-
General17 hours agoAustralian share market set to dive as threat of US recession grows